SCHEDULE: Goldman Sachs Reports Stake in Oaktree Acquisition Corp III

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported beneficial ownership of 6.2% of Oaktree Acquisition Corp III Life Sciences' Class A ordinary shares as of March 31, 2026.

Summary

• This filing is a Schedule 13G, indicating a passive investment stake.
• The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC collectively beneficially own 1,228,500 shares of Oaktree Acquisition Corp III Life Sciences Class A ordinary shares.
• This ownership represents 6.2% of the class of securities.
• The filing date is April 28, 2026, reflecting the ownership as of March 31, 2026.
• Goldman Sachs & Co. LLC is identified as a broker-dealer and investment adviser.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates a significant passive stake by a major financial institution but provides no operational or financial performance data for the issuer itself.

Positives

• Goldman Sachs, a major financial institution, holds a significant passive stake, which could be interpreted as a positive signal regarding the company's potential.
• The filing indicates a passive investment strategy, suggesting no intent to control or influence the issuer's management.

Negatives

• The filing does not contain any financial performance data or operational updates for Oaktree Acquisition Corp III Life Sciences, limiting the ability to assess the company's health.
• The passive nature of the stake means it does not necessarily reflect a strong conviction in the company's future performance, but rather a portfolio holding.

Risks

• As a special purpose acquisition company (SPAC), Oaktree Acquisition Corp III Life Sciences faces the inherent risk of failing to complete a business combination within its specified timeframe, potentially leading to dissolution and return of capital to shareholders.
• The specific business combination target for Oaktree Acquisition Corp III Life Sciences is not detailed in this filing, leaving the future direction and success of the company uncertain.
• Market volatility and economic conditions could impact the success of any future business combination and the value of the shares.

Future Outlook

This filing is a passive ownership report and does not contain forward-looking statements or guidance from Oaktree Acquisition Corp III Life Sciences. The future outlook for the company is dependent on its ability to identify and complete a business combination.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."
• "This filing reflects the securities beneficially owned by certain operating units (collectively, the "Goldman Sachs Reporting Units") of The Goldman Sachs Group, Inc. and its subsidiaries and affiliates (collectively, "GSG")."
• "The Goldman Sachs Reporting Units disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both, or with respect to which there are limits on their voting or investment authority or both and (ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units."

Industry Context

StockSavvy.ai notes that Schedule 13G filings from major financial institutions like Goldman Sachs often indicate a passive investment strategy. For a SPAC like Oaktree Acquisition Corp III Life Sciences, such a filing suggests that Goldman Sachs is holding shares as part of its investment portfolio, rather than actively seeking to influence the company's direction, which is typical for institutional investors in the SPAC market.

Stakeholder Impact

• Shareholders of Oaktree Acquisition Corp III Life Sciences may view Goldman Sachs's stake as a sign of institutional interest, though the passive nature limits direct impact on immediate company strategy.
• Creditors and suppliers are not directly impacted by this filing, as it pertains to equity ownership and not debt or operational agreements.

Next Steps

• Oaktree Acquisition Corp III Life Sciences is expected to identify and complete a business combination.
• Goldman Sachs will continue to hold its shares, subject to its investment strategy and any potential changes in its beneficial ownership.

Key Dates

Keywords

Schedule 13G, Oaktree Acquisition Corp III Life Sciences, Goldman Sachs, Class A ordinary shares, beneficial ownership, passive investment, SPAC, SEC filing